TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12668582
Drug: Intravenous linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous linezolid (500 or 625 mg)
Study: 1671434
Drug: Carbamazepine or
Normalized name: carbamazepine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine or phenobarbitone treatment
Study: 6306348
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and radiation therapy (Cytoxan, CCNU, methotrexate + radiation to brain, chest, and abdomen)
Study: 6306348
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (Cytoxan, CCNU, methotrexate)
Study: 6306348
Drug: Partial response
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial response to therapy
Study: 29178317
Drug: Client‐driven, customized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Client‐driven, customized self‐management program with up to 3 in‐home visits from a registered nurse or registered dietitian, a monthly group wellness program, monthly provider team case conferences, and care coordination and system navigation.
Study: 26739392
Drug: High hs‐TnT
Approvals — FDA: no, EMA: no, PMDA: no
Description: High hs‐TnT level (≥14 ng/l) in diabetic group
Study: 21290836
Drug: Medication (antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (antihistamine and anti-HP infection)
Study: 21290836
Drug: Medication combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication combined with acupoint catgut embedding therapy
Study: 17890862
Drug: ivabradine 5
Normalized name: ivabradine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivabradine 5 mg b.i.d.
Study: 17890862
Drug: ivabradine 7.5
Normalized name: ivabradine 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ivabradine 7.5 mg b.i.d.
Study: 11549982
Drug: Salmeterol xinafoate
Normalized name: Salmeterol Xinafoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol xinafoate 42 mcg via metered dose inhaler twice daily
Study: 9613227
Drug: General light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: General light (G)
Study: 7640145
Drug: Oral sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sumatriptan 200 mg
Study: 1107359
Drug: Intramuscular nefopam
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular nefopam HCl 20 mg
Study: 1107359
Drug: Intramuscular pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular pethidine 50 mg
Study: 1107359
Drug: Oral nefopam
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nefopam HCl 60 mg t.i.d. for three days
Study: 1107359
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo t.i.d. for three days
Study: 20575304
Drug: Sizhi‐Xifang treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sizhi‐Xifang treatment in the treatment group (24 cases) after incision healing
Study: 20575304
Drug: Minimal invasive
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal invasive percutaneous plate treatment in the control group
Study: 19048106
Drug: Amnioreduction (drainage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amnioreduction (drainage of 2000 ml fluid, range 700‐3500 ml)
Study: 11818767
Drug: Clonidine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (10 microg x kg(‐1) administered over 5 min + 5 microg x kg(‐1) x h(‐1) intravenous) given before mu-opioid receptor blockade
Study: 11818767
Drug: Clonidine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (10 microg x kg(‐1) administered over 5 min + 5 microg x kg(‐1) x h(‐1) intravenous) given after mu-opioid receptor blockade
Study: 11818767
Drug: Mu-opioid receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mu-opioid receptor blockade (naloxone)
Study: 7655204
Drug: Mepivacaine 2%
Normalized name: mepivacaine 2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepivacaine 2% (4 ml)
Study: 7655204
Drug: Prilocaine 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prilocaine 2% (4 ml)
Study: 7655204
Drug: Lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2% (4 ml)
Study: 2698273
Drug: Amineptine 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amineptine 200 mg/day
Study: 1099948
Drug: Inhaled isoproterenol
Normalized name: isoproterenol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled isoproterenol hydrochloride
Study: 26351969
Drug: Sertraline hydrochloride,
Normalized name: Sertraline Hydrochloride, 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline hydrochloride, 50 to 100 mg/d
Study: 23432534
Drug: Netazepide (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netazepide (1, 5, 25, and 100 mg)
Study: 23432534
Drug: Netazepide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netazepide (100 mg) twice daily for 13 doses
Study: 11737510
Drug: CHX 0.12%
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHX 0.12% + CPC 0.05% (Perio.Aid, new formulation)
Study: 8989272
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg ALN daily
Study: 8989272
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg ALN daily
Study: 8989272
Drug: 5.0 mg
Normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg ALN daily
Study: 8989272
Drug: ALN (1.0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALN (1.0, 2.5, or 5.0 mg)
Study: 8500697
Drug: Oral meals
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral meals
Study: 29775553
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (PBMT) administered in one upper quadrant (wavelength: 660 nm; Power: 100 mW; Power density: 100 mW/cm2; Energy density per application point = 2 J/cm2; Total dose = 52 J/cm2; Irradiation time: 26 × 20 sec)
Study: 24517720
Drug: Intravaginal progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravaginal progesterone gel (Crinone 8% gel)
Study: 24517720
Drug: Intravaginal progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravaginal progesterone plus oral 2 mg estradiol hemihydrate (E2)
Study: 24517720
Drug: Intravaginal progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravaginal progesterone plus oral 6 mg estradiol hemihydrate (E2)
Study: 11700410
Drug: Methylprednisolone (MP)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (MP) 15 mg/kg
Study: 11700410
Drug: Tirilazad mesylate
Normalized name: tirilazad mesylate
DrugBank: Tirilazad (DB13050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirilazad mesylate (TM) 10 mg/kg
Study: 7697692
Drug: Insulin-glipizide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-glipizide (5 mg/d)
Study: 7697692
Drug: Insulin-placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-placebo
Study: 3316301
Drug: Tiapamil 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiapamil 300 to 600 mg bid
Study: 3316301
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) 25 to 50 mg bid
Study: 29731633
Drug: Once-monthly paliperidone
Normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Once-monthly paliperidone palmitate initiated </=1 week after hospitalization
Study: 29731633
Drug: Once-monthly paliperidone
Normalized name: Paliperidone
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Once-monthly paliperidone palmitate initiated >1 week after hospitalization
Study: 22997786
Drug: Moxibustion treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion treatment (suspended moxibustion applied to Yanglingquan for 15 min, massage device used on pain area, self-help or mutual-aid treatment)
Study: 22997786
Drug: Plaster application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plaster application (Goupi Gao applied to local pain area, treatment once daily for 5 days)
Study: 20129478
Drug: Proactive telephone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proactive telephone breastfeeding support (2 weeks of daily calls by nurses)
Study: 8236580
Drug: Oxytocin injections
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin injections during the first and second postoperative day
Study: 8236580
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections during the first and second postoperative day
Study: 31153628
Drug: Transmuscular quadratus
Normalized name: Pisum quadratum whole
DrugBank: Pisum sativum whole (DB15545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transmuscular quadratus lumborum (TQL) block with ropivacaine 0.75%, 30 ml
Study: 31153628
Drug: Saline 30
Normalized name: Simply Saline 30 MG/ML Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 30 ml (control)
Study: 26759107
Drug: First line
Normalized name: ALCOHOL 0.75 mL in 1 mL TOPICAL CLOTH [First Line Alcohol Wipes]
Approvals — FDA: no, EMA: no, PMDA: no
Description: First line treatment in therapy group
Study: 24391801
Drug: ART with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ART with concurrent active TB
Study: 24391801
Drug: ART without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ART without concurrent TB or other AIDS-defining disease
Study: 10683436
Drug: Conjugated linoleic
Normalized name: CONJUGATED LINOLEIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated linoleic acid (CLA) 4.2 g/day for 3 months
Study: 31718542
Drug: Multimodal training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal training programme (MTP) with Integrated Brief Systemic Therapy (IBST) approach
Study: 22277987
Drug: Transdermal 17β‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17β‐estradiol plus cyclical micronized progesterone for 3 months
Study: 20350191
Drug: MVA (ACAM3000)
Normalized name: MVA
DrugBank: Modified vaccinia ankara (DB15483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA (ACAM3000) administered intradermally at 1 x 10(7) TCID(50)
Study: 20350191
Drug: MVA (ACAM3000)
Normalized name: MVA
DrugBank: Modified vaccinia ankara (DB15483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MVA (ACAM3000) administered intramuscularly or subcutaneously at 1 x 10(8) TCID(50)
Study: 15945400
Drug: promethazine 25
Normalized name: promethazine 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: promethazine 25 mg
Study: 15945400
Drug: promethazine 25
Normalized name: promethazine 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: promethazine 25 mg plus pseudoephedrine 60 mg
Study: 15945400
Drug: promethazine 25
Normalized name: promethazine 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: promethazine 25 mg plus d‐amphetamine 10 mg
Study: 12841887
Drug: Levormeloxifene (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levormeloxifene (four different doses) for 12 months
Study: 12841887
Drug: Raloxifene (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene (three different doses) for 24 months
Study: 1745622
Drug: Acetaminophen 1000
Normalized name: acetaminophen 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1000 mg plus codeine phosphate 60 mg (APAPCOD)
Study: 6285814
Drug: Ketoconazole after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole after fasting (200 mg)
Study: 6285814
Drug: Ketoconazole with
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole with orange juice (300 ml) (brand 1)
Study: 6285814
Drug: Miconazole after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miconazole after fasting (250 mg)
Study: 24499492
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg NRL001
Study: 24499492
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg NRL001
Study: 24499492
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg NRL001
Study: 24499492
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g suppository (NRL001)
Study: 24499492
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g suppository (NRL001)
Study: 24499492
Drug: NRL001 (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: NRL001 (up to 15 mg)
Study: 21791543
Drug: Pharmacist-led intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led intervention to optimize pharmacological therapy
Study: 19402341
Drug: Commercial tablets
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial tablets (COM) 150 mg
Study: 19402341
Drug: Magistral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magistral suspension (MAG) 150 mg
Study: 19402341
Drug: Magistral suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magistral suspension (MAG)
Study: 19402341
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (COM and MAG)
Study: 11845943
Drug: adapalene gel
Normalized name: Adapalene Gel
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: adapalene gel 0.1%
Study: 11845943
Drug: tretinoin microsphere
Normalized name: tretinoin microsphere
Approvals — FDA: no, EMA: no, PMDA: no
Description: tretinoin microsphere gel 0.1%
Study: 28196003
Drug: Bictegravir (BIC)
DrugBank: Bictegravir (DB11799)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bictegravir (BIC) 5 mg
Study: 28196003
Drug: Bictegravir (BIC)
DrugBank: Bictegravir (DB11799)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bictegravir (BIC) 25 mg
Study: 28196003
Drug: Bictegravir (BIC)
DrugBank: Bictegravir (DB11799)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bictegravir (BIC) 50 mg
Study: 28196003
Drug: Bictegravir (BIC)
DrugBank: Bictegravir (DB11799)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bictegravir (BIC) 100 mg
Study: 24617242
Drug: Routine drug
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine drug anesthesia (group A)
Study: 17375114
Drug: Low-energy parenteral
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy parenteral nutrition without amino acids
Study: 17375114
Drug: Low-energy parenteral
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy parenteral nutrition containing amino acids (two types)
Study: 16533223
Drug: Maintenance narrow-band
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance narrow-band UVB therapy for 2 months
Study: 16533223
Drug: Maintenance narrow-band
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance narrow-band UVB therapy for plaque-type psoriasis
Study: 16533223
Drug: No maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: No maintenance therapy for plaque-type psoriasis
Study: 8880107
Drug: Inhaled salmeterol
Normalized name: salmeterol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled salmeterol 100 micrograms b.d.
Study: 8880107
Drug: Inhaled salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled salbutamol 400 micrograms q.d.s.
Study: 1325319
Drug: Placebo (saline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline, 150 mmol/l NaCl)
Study: 29912429
Drug: Oxygen therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen therapy at 6 L/min for 6-12 hours
Study: 24799602
Drug: Low 25(OH)D
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low 25(OH)D levels (<32 ng/mL)
Study: 16824243
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural infusion of 0.2% ropivacaine (group EPI, n = 21)
Study: 16824243
Drug: Paravertebral infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paravertebral infusion of 0.2% ropivacaine (group PVB, n = 21)
Study: 9191873
Drug: OK-432 (picibanil)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OK-432 (picibanil) administered ID twice weekly for 3 months at dosages ranging from 1 KE to 20 KE
Study: 9191873
Drug: OK-432 (picibanil)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OK-432 (picibanil) administered ID twice weekly for 3 months
Study: 7693476
Drug: Nutrizym GR
Normalized name: SALICYLIC ACID 20 mg in 1 mL TOPICAL LIQUID [NUTRIXYL ANTI-DANDRUFF]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrizym GR (standard preparation)
Study: 26509361
Drug: Fentanyl sublingual
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl sublingual spray (median dose = 800 mcg)
Study: 25370587
Drug: Intravenous alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alteplase (0.9 mg/kg) plus standard care
Study: 21118175
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of bisoprolol and ivabradine (mean dose 10.7±3.1 mg/day)
Study: 21118175
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of bisoprolol and ivabradine
Study: 16603801
Drug: Cumulative sums
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative sums (cusums) method with hourly readings
Study: 1442344
Drug: Steroid regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid regimen A (7 weeks duration)
Study: 1442344
Drug: Steroid regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid regimen B (15 weeks duration)
Study: 31874985
Drug: treatment cream
Normalized name: Acne Treatment Cream
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment cream
Study: 31874985
Drug: control cream
Normalized name: BENZOYL PEROXIDE 3 mg in 60 mL TOPICAL LIQUID [Acnecare Dermacontrol Cream]
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: control cream
Study: 31874985
Drug: anticipatory treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: anticipatory treatment cues
Study: 26111957
Drug: palonosetron (0.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: palonosetron (0.25, 0.75, or 2.25 mg)
Study: 26111957
Drug: moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: moxifloxacin (400 mg)
Study: 24621778
Drug: Sitagliptin in
Normalized name: Product containing sitagliptin in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin in combination with CSII therapy
Study: 24621778
Drug: CSII monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSII monotherapy
Study: 20451686
Drug: P‐OM3 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: P‐OM3 4 g/day
Study: 19818685
Drug: Fluorouracil (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil (800 mg/m2 per day, days 1-5, every 4 weeks)
Study: 19818685
Drug: Irinotecan plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan plus cisplatin (irinotecan 70 mg/m2 on days 1 and 15, cisplatin 80 mg/m2 on day 1, every 4 weeks)
Study: 19818685
Drug: S-1 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 (40 mg/m2 twice a day, days 1-28, every 6 weeks)
Study: 11697841
Drug: Docetaxel at
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel at 100 mg/m2 every three weeks (with a switch to 40 mg/m2 weekly in case of severe toxicity)
Study: 9596428
Drug: oxymetazoline nasal
Normalized name: oxymetazoline nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxymetazoline nasal spray (0.05%)
Study: 9596428
Drug: double placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: double placebo (capsule and nasal spray)
Study: 7869015
Drug: Monospecific antivenin
Normalized name: ANTIVENIN,CROTALIDAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monospecific antivenin therapy (60 ml administered intravenously at 6-hour intervals until blood coagulability is restored)
Study: 7869015
Drug: Monospecific antivenin
Normalized name: ANTIVENIN,CROTALIDAE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monospecific antivenin therapy
Study: 3215145
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose T3 administration (25 micrograms per day for 4 weeks)
Study: 28796588
Drug: G-CHOP (Obinutuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CHOP (Obinutuzumab plus CHOP)
Study: 24951296
Drug: Nitrate-rich beetroot
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate-rich beetroot juice (70 mL) consumed 150 min before the first time trial
Study: 24951296
Drug: Nitrate-rich beetroot
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate-rich beetroot juice (70 mL) consumed 75 min before the first time trial
Study: 24951296
Drug: Nitrate-rich beetroot
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate-rich beetroot juice (35 mL top-up dose) after the first time trial
Study: 19744307
Drug: Endocrine and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine and cytotoxic therapies
Study: 16244017
Drug: Intraoperative IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative IV ondansetron (4 mg) followed by postoperative ondansetron (8 mg BID for up to 72 h)
Study: 12107603
Drug: Digitoxin (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digitoxin (0.6 mg day 1, 0.4 mg day 2, then 0.1 mg daily)